Concord Biotech Q2 FY27 Earnings Call — Analysis (NSE: CONCORDBIO)
Concord Biotech delivered 25% revenue growth in Q2FY27 driven by API traction (up 30%), though EBITDA margins contracted to 33.8% due to raw material inflation and operational drag from nascent injectables and US front-end subsidiary Stellon.
Result quality: watch — Margin pressure. Management sentiment: optimistic.
The take
Q2FY27 Revenue from Operations ₹309.1 Cr ( +25% YoY ) . Guidance raised .
Results
Revenue grew 25% YoY to ₹309.1 Cr with EBITDA margin of 33.8% (up 18% YoY to ₹104.4 Cr) and PAT up 10.3% YoY to ₹69.6 Cr, burdened by ~400 bps gross margin contraction and startup costs in injectables and Stellon.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹309.1 Cr | +25% | yoy · Q2FY27 |
| Revenue from Operations | ₹566.6 Cr | +26% | yoy · H1FY27 |
| API Revenue | ₹250.1 Cr | +30% | yoy · Q2FY27 |
| Formulations Revenue | ₹58.9 Cr | +6% | yoy · Q2FY27 |
| Gross Margin | 76.2% | -400bps | yoy · Q2FY27 |
| EBITDA | ₹104.4 Cr | +18% | yoy · Q2FY27 |
| EBITDA Margin | 33.8% | none · Q2FY27 · 37.1% ex-injectables & Stellon | |
| EBITDA | ₹187 Cr | +25% | yoy · H1FY27 |
| EBITDA Margin | 33.0% | -20bps | yoy · H1FY27 · 37.8% ex-injectables & Stellon |
| Profit After Tax | ₹69.6 Cr | +10.3% | yoy · Q2FY27 |
| Profit After Tax | ₹127.3 Cr | +19% | yoy · H1FY27 · 23% YoY ex-JV share of profit |
| Cash and Cash Equivalents | ₹445 Cr | point_in_time · Q2FY27 · 30-Sep-2026 |
Guidance
Management expects full-year FY27 revenue growth to exceed its historical ~18% rate, with EBITDA margins returning to 38-40% over the medium term as injectables and Stellon ramp up.
Key themes
API broad-based recovery and formulation ramp-up
Operational commentary
- Capacity utilization across plants: Unit I at 75%, Unit II (oral solids) at 21%, Unit III (Limbasi) at 55%, and Unit IV (injectables) at 5%.
- Regulatory milestones: Received ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension; filed US DMF for Fidaxomicin; completed USFDA inspection at Unit II (Valthera) and received ANVISA approval for Unit III (Limbasi).
- Launched 'Inspira', a new dermatology division targeting a ₹5,000 Cr addressable market in India across eczema, acne, and anti-infectives.
- Formulation business in US transitioning to wholly owned subsidiary Stellon Biotech, with supplies commenced for commercial roll-out in H2FY27.
- Shareholder approval received for a 1:1 bonus share issue.
Analyst Q&A
Q. Drivers of gross margin contraction and whether price hikes can be passed on to customers?
Gross margin contracted ~400 bps YoY mainly due to raw material and solvent price inflation and product mix. Management noted it is difficult and unnecessary to pass on short-term costs to customers, preferring internal R&D/productivity improvements.
Q. Timeline for injectable contract closures and facility ramp-up?
Several global and domestic customer audits have been completed; management expects commercial contracts to materialize in H2FY27, targeting ₹300 Cr top-line over 3-4 years.
Q. Status and revenue outlook of the CDMO business?
Currently Concord has one commercial CDMO project generating ~$2M annually with an NCE innovator in the US, plus several smaller R&D development stage projects.
Research and educational content only. Not investment advice.